Form 8-K - Current report:
SEC Accession No. 0001193125-22-225373
Filing Date
2022-08-19
Accepted
2022-08-19 16:33:57
Documents
16
Period of Report
2022-08-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d358498d8k.htm   iXBRL 8-K 29179
2 EX-1.1 d358498dex11.htm EX-1.1 246543
3 EX-5.1 d358498dex51.htm EX-5.1 6522
7 GRAPHIC g358498dsp51.jpg GRAPHIC 3838
8 GRAPHIC g358498dsp51a.jpg GRAPHIC 4479
  Complete submission text file 0001193125-22-225373.txt   484506

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20220816.xsd EX-101.SCH 2885
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20220816_lab.xml EX-101.LAB 17996
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20220816_pre.xml EX-101.PRE 11281
10 EXTRACTED XBRL INSTANCE DOCUMENT d358498d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 221181276
SIC: 8071 Services-Medical Laboratories